Figure 6.

Regression of established C3 tumors after treatment with the E7 peptide and mAb 2A. Mice were injected subcutaneously with 1 × 10⁶ C3 cells. Seven days later, mice were divided into two groups and were immunized intradermally with either Vp2 or E7 peptide (50 μg/mouse) emulsified in IFA. On days 7 and 10, mice received 100 μg of the control rat IgG or mAb 2A intraperitoneally. Tumor size was assessed weekly for each mouse, and the mice were sacrificed at the times indicated, when the average tumor diameter reached 15 mm (filled circles). Mice bearing tumors less than an average of 15 mm in diameter were sacrificed upon termination of the experiment, at 13 weeks (open circles). Data was combined from two similarly performed experiments. The improved survival observed in the treatment group receiving both the E7 peptide and mAb 2A was statistically significant, as determined by the χ² test. (P ≤ 0.01).